Characterization of hepatitis B virus infection and viral <scp>DNA</scp> integration in non‐Hodgkin lymphoma

Li, Mengge; Shen, Yanwei; Chen, Yiming; Gao, Haifeng; Zhou, Jun; Wang, Qing; Chen, Fan; Zhang, Wei; Jin, Li; Cong, Hui; Gu, Jinyang; Gan, Yu; Tu, Hong

doi:10.1002/ijc.33027

Cited by 36 publications

(28 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EGFLAM , a protein coding gene which plays a role in matrix assembly and cell adhesiveness was associated with higher risk of reporting moderate to severe xerostomia. It is considered a biomarker in some cancers including a hypomethylated tumor maker in ovarian cancer 53 and with altered expression in non-Hodgkin lymphoma 54 . Importantly, expression of this gene correlates with cell proliferation, migration, invasion, and poor prognosis by activating the P13/AKT pathway in Glioblastoma 55 .…”

Section: Discussionmentioning

confidence: 99%

Genetic susceptibility to patient-reported xerostomia among long-term oropharyngeal cancer survivors

Aggarwal

Hutcheson

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Genetic susceptibility for xerostomia, a common sequela of radiotherapy and chemoradiotherapy for head and neck cancer, is unknown. Therefore, to identify genetic variants associated with moderate to severe xerostomia, we conducted a GWAS of 359 long-term oropharyngeal cancer (OPC) survivors using 579,956 autosomal SNPs. Patient-reported cancer treatment-related xerostomia was assessed using the MD Anderson Symptom Inventory. Patient response was dichotomized as moderate to severe or none to mild symptoms. In our study, 39.2% of OPC survivors reported moderate to severe xerostomia. Our GWAS identified eight SNPs suggestively associated with higher risk of moderate to severe xerostomia in six genomic regions (2p13.3, rs6546481, Minor Allele (MA) = A, ANTXR1, P = 4.3 × 10–7; 5p13.2–p13.1, rs16903936, MA = G, EGFLAM, P = 5.1 × 10–6; 4q21.1, rs10518156, MA = G, SHROOM3, P = 7.1 × 10–6; 19q13.42, rs11882068, MA = G, NLRP9, P = 1.7 × 10–5; 12q24.33, rs4760542, MA = G, GLT1D1, P = 1.8 × 10–5; and 3q27.3, rs11714564, MA = G, RTP1, P = 2.9 × 10–5. Seven SNPs were associated with lower risk of moderate to severe xerostomia, of which only one mapped to specific genomic region (15q21.3, rs4776140, MA = G, LOC105370826, a ncRNA class RNA gene, P = 1.5 × 10–5). Although our small exploratory study did not reach genome-wide statistical significance, our study provides, for the first time, preliminary evidence of genetic susceptibility to xerostomia. Further studies are needed to elucidate the role of genetic susceptibility to xerostomia.

show abstract

Section: Discussionmentioning

confidence: 99%

Genetic susceptibility to patient-reported xerostomia among long-term oropharyngeal cancer survivors

Aggarwal

Hutcheson

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…5,10 Especially in cases of ML, genetic evidence revealed HBV as a risk factor. 11,12 The main evidence was the integration of HBV DNA in lymphoid tissue. As a result, the role of HBV integration and oncogenesis had been considered as a promising treatment mechanism.…”

Section: Discussionmentioning

confidence: 99%

Chronic Hepatitis B Viral Activity As A Prognostic Factor For Survival In Malignant Lymphoma

Seo

Kim

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Hepatitis B virus (HBV) infection carries a risk of liver cancer and extrahepatic malignancy. However, the incidence trend and clinical course of malignant lymphoma (ML) in HBV patients are not well known. Methods: Data about ML newly diagnosed in chronic hepatitis B (CHB) patients from 2003 to 2016 were collected from National Health Insurance Service claims. Results: A total of 13,942 CHB patients were newly diagnosed with ML from 2003 to 2016. The number of patients increased 3.8 times, from 442 in 2003 to 1,711 in 2016. The 2-year survival rate of all patients was 76.8%, and the 5-year survival rate was 69.8%. The survival rate of patients taking antivirals due to high viral activity before their diagnosis with ML was significantly lower than that of patients with lower viral activity (1 yr-77.3%, 3 yr-64.5%, and 5 yr-58.3% vs. 1 yr-84.0%, 3 yr-73.4%, and 5 yr-68.0%, respectively). The survival rate of patients with liver cirrhosis (LC) at baseline was significantly lower than that of those without LC. Cirrhotic patients taking antivirals before ML diagnosis had a worse prognosis than who did not. Conclusions: High viral activity in CHB patients with ML is useful in predicting the prognosis for survival.

show abstract

“…Consistent with previous studies, we found that HBV makers assay was different between DLBCL patients and general population. To date, previous studies have been focused on the association between HBsAg, HBV DNA and DLBCL development (20,24,28) and it's found that patients with positive HBsAg had higher risk of DLBCL. In fact, HBsAg-positive patients only account for less than 10% of total DLBCL patients and the progression of lymphoma has been reported to be correlated with host immune response.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, HBV antigen was discovered in lymphoma tissue (20,21) and bone marrow cells from DLBCL patients (22). Besides, HBV DNA existed in peripheral blood mononuclear cells (23) and tumor tissue (20,21,24) from DLBCL patients. Besides, HBV had the ability to infect B lymphocytes in vitro (20) and then the integration of HBV DNA into the host genome was found in lymphoma (24), indicating the potential role of HBV infection in lymphoma development.…”

Section: Introductionmentioning

confidence: 99%

“…Besides, HBV DNA existed in peripheral blood mononuclear cells (23) and tumor tissue (20,21,24) from DLBCL patients. Besides, HBV had the ability to infect B lymphocytes in vitro (20) and then the integration of HBV DNA into the host genome was found in lymphoma (24), indicating the potential role of HBV infection in lymphoma development. However, the potential role and underlying mechanism of HBV infection in lymphoma development has never been reported before.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Hepatitis B Virus Antibody as Potential Biomarker to Predict the Effect of Rituximab in Diffuse Large B-cell Lymphoma Patients

Chen

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Diffuse large B-cell lymphoma (DLBCL) has been correlated with virus infection and immunity status. Hepatitis B virus (HBV) infection is a significant public health problem around the world, especially in China. Previous research regarding the association of non-Hodgkin lymphoma (NHL) and HBV mostly focused on HBV antigen and HBV DNA. This study aimed to evaluate the relationship between HBV antibody and clinical prognosis in DLBCL. Methods: We retrospectively investigated the clinical characteristics of 190 newly diagnosed and untreated DLBCL patients and did a follow-up study. Results: Compared with HBeAb- patients, HBeAb+ patients displayed unique clinical features, such as more advanced disease stage (p=0.031) and higher International Prognostic Index (IPI) score (p=0.015). HBV antibody-negative patients had better therapeutic efficiency than positive patients (p<0.05). The media progression-free survival (PFS) and overall survival (OS) of HBV antibody-positive group were shorter than the negative group, respectively (p<0.05). Furthermore, we found positive association between CD21 and HBsAb (p=0.06) and their synergistic effect for prognostic predication. Interestingly, the effect of Rituximab in prognostic improvement was more significant in HBV antibody-positive group than negative group. Univariate analysis showed that HBV antibody status was independent risk factor for prognosis of DLBCL patients. Conclusions: Taken together, our investigations identified for the first time the close association between HBV antibody and clinical prognosis and Rituximab responses in DLBCL patients. These findings indicate the novel association between HBV infection and DLBCL prognosis, provide potential biomarker to predict the effect of Rituximab, and offer novel insights into the role of immune response to HBV infection in DLBCL progression.

show abstract

Characterization of hepatitis B virus infection and viral DNA integration in non‐Hodgkin lymphoma

Cited by 36 publications

References 44 publications

Genetic susceptibility to patient-reported xerostomia among long-term oropharyngeal cancer survivors

Genetic susceptibility to patient-reported xerostomia among long-term oropharyngeal cancer survivors

Chronic Hepatitis B Viral Activity As A Prognostic Factor For Survival In Malignant Lymphoma

Hepatitis B Virus Antibody as Potential Biomarker to Predict the Effect of Rituximab in Diffuse Large B-cell Lymphoma Patients

Contact Info

Product

Resources

About